Publications Scientifiques
- Izadi, Z, Gianfrancesco, MA, Schmajuk, G, Jacobsohn, L, Katz, P, Rush, S et al.. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study. Lancet Rheumatol. 2022;4 (9):e603-e613. doi: 10.1016/S2665-9913(22)00192-8. PubMed PMID:35909441 PubMed Central PMC9313519.
- Markarian, NM, Galli, G, Patel, D, Hemmings, M, Nagpal, P, Berghuis, AM et al.. Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency. Front Microbiol. 2022;13 :933983. doi: 10.3389/fmicb.2022.933983. PubMed PMID:35847101 PubMed Central PMC9283111.
- Torri, A, Jaeger, J, Pradeu, T, Saleh, MC. The origin of RNA interference: Adaptive or neutral evolution?. PLoS Biol. 2022;20 (6):e3001715. doi: 10.1371/journal.pbio.3001715. PubMed PMID:35767561 PubMed Central PMC9275709.
- Blaye, C, Darbo, É, Debled, M, Brouste, V, Vélasco, V, Pinard, C et al.. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open. 2022;7 (4):100502. doi: 10.1016/j.esmoop.2022.100502. PubMed PMID:35759853 PubMed Central PMC9434232.
- Rosellini, P, Amintas, S, Caumont, C, Veillon, R, Galland-Girodet, S, Cuguillière, A et al.. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. Eur J Cancer. 2022;172 :85-95. doi: 10.1016/j.ejca.2022.05.026. PubMed PMID:35759814 .
- Seneschal, J, Boniface, K, Jacquemin, C. Alopecia areata: Recent advances and emerging therapies. Ann Dermatol Venereol. 2022;149 (4):222-227. doi: 10.1016/j.annder.2022.03.006. PubMed PMID:35752494 .
- Chevalier, L, Cochet, H, Mahida, S, S, SB, Benard, A, Cariou, T et al.. Resuming Training in High-Level Athletes After Mild COVID-19 Infection: A Multicenter Prospective Study (ASCCOVID-19). Sports Med Open. 2022;8 (1):83. doi: 10.1186/s40798-022-00469-0. PubMed PMID:35751748 PubMed Central PMC9233721.
- Iaxx, R, Lefort, F, Domblides, C, Ravaud, A, Bernhard, JC, Gross-Goupil, M et al.. An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. Ther Clin Risk Manag. 2022;18 :619-632. doi: 10.2147/TCRM.S251673. PubMed PMID:35677148 PubMed Central PMC9169675.